Incidental control of rosacea by somatostatin.

Diabetes Mellitus, Type 1/complications; Diabetic Retinopathy/complications/drug therapy; Hormones/therapeutic use; Humans; Male; Middle Aged; Octreotide/therapeutic use; Rosacea/complications/drug therapy; Treatment Outcome

Abstract :

[en] BACKGROUND: The precise pathomechanism of rosacea remains elusive. The disease commonly requires long-term treatments using topical or oral therapies. OBJECTIVE: This report presents incidental findings about the possible modulatory role of somatostatin in the outcome of rosacea. METHOD: Four patients presenting long-standing recalcitrant facial rosacea were treated with octreotide for diabetic retinopathy. RESULTS: Rosacea improved rapidly and even cleared without any recurrence in 3 of the patients. CONCLUSION: The beneficial effect might be attributed to inhibitory actions on the sebaceous gland, the neovascularization and/or on the inflammatory process.

Disciplines :

Dermatology

Author, co-author :

Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

English

Title :

Incidental control of rosacea by somatostatin.

Publication date :

2003

Journal title :

Dermatology

ISSN :

1018-8665

eISSN :

1421-9832

Publisher :

S. Karger, Basel, Switzerland

Volume :

206

Issue :

Pages :

249-51

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 09 March 2009

Statistics

Number of views

42 (4 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Wilkin JK: Rosacea: Pathophysiology and treatment. Arch Dermatol 1994;130:359-362.
Jansen T, Plewig G: Rosacea: Classification and treatment. J R Soc Med 1997;90:144-150.
Weinstock JV, Elliott D: The substance P and somatostatin interferon-gamma immunoregulatory circuit. Ann NY Acad Sci 1998;840: 532-539.
Ten Bokum AM, Hofland LJ, van Hagen PM: Somatostatin and somatostatin receptors in the immune system: A review. Eur Cytokine Netw 2000;1:161-176.
Weinstock JV, Elliott D: The somatostatin immuno-regulatory circuit present at sites of chronic inflammation. Eur J Endocrinol 2000; 143 (suppl 1):S15-S19.
Bonnar E, Eustace P, Powell FC: The Demodex mite population in rosacea. J Am Acad Dermatol 1993;28:443-448.
Sharma VK, Lynn A, Kaminski M, Vasudeva R, Howden CW: A study of the prevalence of Helicobacter pylori infection and other markers of upper gastrointestinal tract disease in patients with rosacea. Am J Gastroenterol 1998; 93:220-222.
Wolina U, Mahrle G: Epidermal Merkel cells in psoriatic lesions: Immuno-histochemical investigations on neuroendocrine antigen expression. J Dermatol Sci 1992;3:145-150.
Johansson O, Hilliges M, Talme T, Marcusson JA, Wetterberg L: Somatostatin immunoreactive cells in psoriatic human skin during peptide T treatment. Acta Derm Venereol 1994;74:106-109.
Gaudillère A, Misery L, Bernard C, Souchier C, Claudy A, Schmitt D: Presence of somatostatin in normal human epidermis. J Invest Dermatol 1997;137:376-380.
Talme T, Schultzberg M, Sundqvist KG, Marcusson JA: Colocalization of somatostatin and HLA-DR-like immunoreactivity in dendritic cells of psoriatic skin. Acta Derm Venereol 1997;77:338-342.
Talme T, Schultzberg M, Sundqvist K, Marcusson J: Somatostatin- and factor XIIIa- immunoreactive cells in psoriasis during clobetasol propionate and calcipotriol treatment. Acta Derm Venereol 1999;79:44-48.
Guilhou JJ, Boulanger A, Barneon G, Vie P, Meynadier J, Tardiau JC, Clot J: Somatostatin treatment of psoriasis. Arch Dermatol Res 1982;274:249-257.
Weber G, Klughart G, Neidhardt N, Galle K, Frey H, Geiger A: Treatment of psoriasis with somatostatin. Arch Dermatol Res 1982;272:31-36.
Venier A, De Simone C, Forni L, Ghirlanda G, Vecioli L, Serri F, Frati L: Treatment of severe psoriasis with somatostatin: Four years of experience. Arch Dermatol Res 1988;280:S51-S54.
Matt LH, Kingston TP, Lowe NJ: Treatment of severe psoriasis with intravenous somatostatin. J Dermatol Treat 1989;181:81-82.
Camisa C: Somatostatin and a long-acting analogue, octreotide acetate: Relevance to dermatology. Arch Dermatol 1989;125:407-412.
Descamps V, Duval X, Crickx B, Bouscarat F, Coffin B, Belaich S: Global improvement of systemic scleroderma under long-term administration of octreotide. Eur J Dermatol 1999;9: 446-448.
Boehm BO, Lang GK, Jehle PM, Feldmann B, Lang GE: Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res 2001;33:300-306.
Wilkin J, Dahl M, Detmar M, Drake I, Feinstein A, Odom R, Powell F: Standard classification of rosacea: Report of the national rosacea society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002;46:584-587.
Deplewski D, Rosenfield RL: Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology 1999;140:4089-4094.
Piérard GE, Piérard-Franchimont C, Marks R, Paye M, Rogiers V, the EEMCO group: EEMCO guidance for the in vivo assessment of skin greasiness. Skin Pharmacol Appl Skin Physiol 2000;13:372-389.
Slominski A, Wortsman J: Neuroendocrinology of the skin. Endocr Rev 2000;21:457-487.
Payan DG, Hess CA, Goetzl EJ: Inhibition by somatostatin of the proliferation of T-lymphocytes and molt-4 lymphoblasts. Cell Immunol 1984;84:433-438.
Stanisz AM, Scicchitano R, Payan DG, Bienenstock J: In vitro studies of immunoregulation by substance P and somatostatin. Ann NY Acad Sci 1987;496:217-225.
Kolasinski S, Haines K, Siegel E, Cronstein BN, Abramson SB: Neuropeptides and inflammation: A somatostatin analog as a selective antagonist of neutrophil activation by substance P. Arthritis Rheum 1992;35:369-375.
Karalis K, Mastorakos G, Sano H, Wilder RL, Chronsos GP: Somatostatin may participate in the anti-inflammatory actions of glucocorticoids. Endocrinology 1995;136:4133-4138.
Elliott DE, Li J, Blum A, Metwali A, Patel YC, Weinstock JV: SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999;29:2454-2463.
Guarrera M, Brusati C, Rebora A: Topical metronidazole does not abate UVB-induced erythema. Dermatology 2001;203:121-123.
Vienne MP, Ochando N, Borrel MT, Gall Y, Lauze C, Dupuy P: Retinaldehyde alleviates rosacea. Dermatology 1999;199(suppl 1):53-56.
Koçak M, Yaǧli S, Vahapoǧlu G, Ekşioglu M: Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular Rosacea. Dermatology 2002;205:265-270.
Naldi L, Braun R, Saurat JH: Evidence-based dermatology: A need to reset the agenda. Dermatology 2002;204:1-4.